Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hairy cell leukaemia

L C Platanias1, H M Golomb

  • 1Division of Hematology-Oncology, Loyola University Chicago-Stritch School of Medicine, Maywood, IL 60153.

Bailliere'S Clinical Haematology
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma.

Oncogene·2017
Same author

Late Relapse in Hodgkin's Disease: Report of Five Cases and a Review of the Literature.

Leukemia & lymphoma·2016
Same author

Survival Experience of 195 Patients with Hairy Cell Leukemia Treated in a Multi-Institutional Study with Interferon-Alfa 2B.

Leukemia & lymphoma·2016
Same author

Familial Lymphoproliferative Disorders with Chromosomal Fragile Site Analysis.

Leukemia & lymphoma·2016
Same author

Low Dose Interferon Alfa-2B for the Induction of Remission of Hairy Cell Leukemia: A Multi-institutional Study of 49 Patients.

Leukemia & lymphoma·2016
Same author

HDS: Establishment of a New Cell Line from a Hairy Cell Leukemia Patient with Resistance to Alpha-Interferon Therapy.

Leukemia & lymphoma·2016

Hairy cell leukaemia is a rare cancer requiring treatment for symptoms like low blood counts. Newer drugs like pentostatin and 2-chlorodeoxyadenosine offer high remission rates, potentially curing some patients.

Area of Science:

  • Hematology
  • Oncology
  • Rare Diseases

Background:

  • Hairy cell leukaemia (HCL) is a rare chronic lymphoproliferative disorder.
  • Characterized by splenomegaly, pancytopenia, and infections, HCL typically requires therapy for progressive disease.
  • Treatment initiation is often prompted by neutropenia or severe thrombocytopenia.

Purpose of the Study:

  • To review therapeutic options for hairy cell leukaemia.
  • To compare the efficacy of splenectomy, interferon, pentostatin, and 2-chlorodeoxyadenosine in HCL treatment.

Main Methods:

  • Review of existing literature on hairy cell leukaemia treatments.
  • Analysis of remission rates and long-term outcomes for various therapeutic modalities.

Main Results:

Related Experiment Videos

  • Splenectomy is indicated for specific patient groups with minimal bone marrow involvement.
  • Interferon induces remission in most patients but complete remission is rare (5-10%).
  • Pentostatin achieves complete remission in 60-70% and partial remission in 20-40%.
  • 2-Chlorodeoxyadenosine shows high efficacy, inducing long-lasting complete remission in approximately 80% of patients.

Conclusions:

  • Pentostatin and 2-chlorodeoxyadenosine are highly effective treatments for hairy cell leukaemia.
  • These purine analogue chemotherapies may offer a potential cure for a subset of HCL patients.
  • Further long-term follow-up is necessary to confirm curative potential.